Can Oral Orforglipron Revolutionize Insulin Therapy?

Managing type 2 diabetes with basal insulin frequently leads to weight gain and increased hypoglycemic risk. Consequently, clinicians often struggle to intensify therapy. However, the introduction of oral orforglipron provides a promising alternative to mitigate these clinical challenges.

The Clinical Impact of Oral Orforglipron

Recently, the ACHIEVE-5 phase 3 trial investigated the effects of adding this once-daily, nonpeptide GLP-1 receptor agonist to titrated insulin glargine. Specifically, the study evaluated adult patients who previously demonstrated inadequate glycemic control on their basal insulin regimens. Therefore, researchers randomized 546 participants to receive different doses of the drug or a placebo over a 40-week period. Crucially, the primary outcome assessed the mean change in HbA1c from baseline to week 40.

Key Findings and Efficacy Data

Additionally, the results showed that all dosages of the oral drug were significantly superior to placebo. For example, patients taking the 12-mg and 36-mg daily doses experienced impressive HbA1c reductions of 1.88% and 1.82%, respectively. On the other hand, the placebo group only achieved a minor reduction of 0.79%. Furthermore, a substantial percentage of participants successfully achieved target HbA1c levels below 7.0%. Surprisingly, these glycemic improvements occurred alongside notable body weight reductions across all treatment groups.

Safety Profile and Tolerability

Despite the therapeutic benefits, gastrointestinal side effects occurred more frequently in patients receiving the active treatment. In contrast, the overall rate of severe hypoglycemia remained remarkably low and comparable to the placebo group. Therefore, adding this therapy to titrated insulin does not appear to compromise patient safety. However, clinicians should monitor patients for transient pulse rate elevations during treatment initiation.

Frequently Asked Questions

Q1: What is oral orforglipron?

Oral orforglipron is a novel, once-daily, nonpeptide glucagon-like peptide 1 (GLP-1) receptor agonist designed to improve glycemic control and reduce body weight without food or water restrictions.

Q2: Did patients in the ACHIEVE-5 trial experience significant weight loss?

Yes, patients receiving the active treatment achieved body weight reductions between 2.6% and 5.4%, whereas the placebo group experienced slight weight gain.

References

1. Giorgino F et al. Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial. JAMA. 2026 Jun 07. doi: 10.1001/jama.2026.9512. PMID: 42251769.
2. Gadde KM, et al. Mazdutide and orforglipron — new oral and injectable options for diabetes. JAMA. 2026 Jun 07. doi: 10.1001/jama.2026.9513.